Announcements
- Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)
- G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) Meeting
- G1 Therapeutics and Deimos Biosciences Announce Global (Excluding Asia-Pacific) License Agreement for Lerociclib for Radioprotective Uses
- G1 Therapeutics Provides First Quarter 2024 Financial Results and Operational Highlights
- G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib
- G1 Therapeutics Provides Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
- G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy
- G1 Therapeutics Announces Upcoming Presentation at the 2023 San Antonio Breast Cancer Symposium
More ▼
Key statistics
As of last trade G1 Therapeutics Inc (G1H:MUN) traded at 3.13, -31.67% below its 52-week high of 4.58, set on May 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.13 |
---|---|
High | 3.13 |
Low | 3.13 |
Bid | 2.93 |
Offer | 3.03 |
Previous close | 3.13 |
Average volume | 1.43k |
---|---|
Shares outstanding | 52.28m |
Free float | 46.78m |
P/E (TTM) | -- |
Market cap | 172.53m USD |
EPS (TTM) | -0.6146 USD |
Data delayed at least 15 minutes, as of Jun 03 2024 07:16 BST.
More ▼